Pediatric Infectious Disease

Register      Login

VOLUME 5 , ISSUE 2 ( April-June, 2023 ) > List of Articles

Original Article

Profile of Multisystem Inflammatory Syndrome in Children Related to COVID-19: A Multicentric Study from South India

Sagar Bhattad, Ramya Sadashiva, Rachna S Mohite, Karthik Arigela, Syed M Naushad, Jeeson Unni, Rajappan Pillai, Gladys Cyril, George Paul, Sathish Kumar, Manjula Anand, Vinitha Anirudhan, Sujatha Thyagarajan, Sangeetha Budur, Sindhu Malvel, Jyothi Raghuram, Srinivasa Murthy, Lathiesh Kumar, Chetan Ginigeri

Keywords : Anti-severe complication of severe acute respiratory syndrome coronavirus 2 antibodies, Coronavirus disease 2019, Intravenous immunoglobulin, Multisystem inflammatory syndrome in children, Myocardial dysfunction, Kawasaki disease

Citation Information : Bhattad S, Sadashiva R, Mohite RS, Arigela K, Naushad SM, Unni J, Pillai R, Cyril G, Paul G, Kumar S, Anand M, Anirudhan V, Thyagarajan S, Budur S, Malvel S, Raghuram J, Murthy S, Kumar L, Ginigeri C. Profile of Multisystem Inflammatory Syndrome in Children Related to COVID-19: A Multicentric Study from South India. Pediatr Inf Dis 2023; 5 (2):37-41.

DOI: 10.5005/jp-journals-10081-1390

License: CC BY-NC 4.0

Published Online: 30-06-2023

Copyright Statement:  Copyright © 2023; The Author(s).


Multisystem inflammatory syndrome in children (MIS-C) is a severe complication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection associated with significant morbidity and can be fatal if left unrecognized. A retrospective multicentric study was carried out at five tertiary care centers in South India, to evaluate the clinical profile of children admitted with MIS-C associated with SARS-CoV-2 infection. Cases of MIS-C diagnosed during October 2020 to December 2021 were included. Diagnosis of MIS-C was based on World Health Organization (WHO) criteria. All children underwent echocardiography at admission, discharge, and 4–6 weeks of follow-up. Children with MIS-C were treated with intravenous immunoglobulin (IVIG) and/or steroids. We compared younger children (<5 years of age) with older ones to determine if age at presentation could predict severity in children with MIS-C. A total of 81 children were diagnosed to have MIS-C during the study period. The mean age of presentation was 6.8 years. Around 29.6% of the children had a shock at admission and 54.3% had myocardial dysfunction. The average duration of a pediatric intensive care unit (PICU) stay was 6.6 days. Anti-SARS-CoV-2 antibodies were found to be positive in 75.3% of patients. Children with high N-terminal prohormone of brain natriuretic peptide (NT-proBNP) had more severe presentations. All children responded promptly to IVIG and steroids and the mortality was 0%. No difference was noted in terms of outcome between younger (<5 years) and older children. A significant proportion of children with MIS-C present with shock and myocardial dysfunction. Anti-SARS-CoV-2 antibodies were positive in 75% of children whose primary infection went unnoticed. We hereby report one of the largest cohorts of MIS-C patients from the Indian subcontinent.

  1. Godfred-Cato S, Bryant B, Leung J, et al. COVID-19–associated multisystem inflammatory syndrome in children—United States, March–July 2020. MMWR Morb Mortal Wkly Rep 2020;69(32): 1074–1080. DOI: 10.15585/mmwr.mm6932e2
  2. Belot A, Antona D, Renolleau S, et al. SARS-CoV-2-related paediatric inflammatory multisystem syndrome, an epidemiological study, France, 1 March to 17 May 2020. Euro Surveill 2020;25(22):2001010. DOI: 10.2807/1560-7917.ES.2020.25.22.2001010
  3. Whittaker E, Bamford A, Kenny J, et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA 2020;324(3):259–269. DOI: 10.1001/jama.2020.10369
  4. Ramcharan T, Nolan O, Lai CY, et al. Paediatric inflammatory multisystem syndrome: temporally associated with SARS-CoV-2 (PIMS-TS): cardiac features, management and short-term outcomes at a UK tertiary paediatric hospital. Pediatric Cardiol 2020;41(7): 1391–1401. DOI: 10.1007/s00246-020-02391-2
  5. Alsaied T, Tremoulet AH, Burns JC, et al. Review of cardiac involvement in multisystem inflammatory syndrome in children. Circulation 2021;143(1):78–88. DOI: 10.1161/CIRCULATIONAHA.120.049836
  6. Ouldali N, Toubiana J, Antona D, et al. Association of intravenous immunoglobulins plus methylprednisolone vs immunoglobulins alone with course of fever in multisystem inflammatory syndrome in children. JAMA 2021;325(9):855–864. DOI: 10.1001/jama.2021.0694
  7. Multisystem inflammatory syndrome in children and adolescents with COVID-19. Scientific brief:. World Health Organisation. 2020. Available from: detail/multisysteminflam-matory-syndrome-in-children- andadolescents-with-covid-19. [Last accessed on July 15, 2020].
  8. McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation 2017;135(17):e927–e999. DOI: 10.1161/CIR.0000000000000484
  9. Bhat CS, Gupta L, Balasubramanian S, et al. Hyperinflammatory syndrome in children associated with COVID-19: need for awareness. Indian Pediatr 2020;57(10):929–935. DOI: 10.1007/s13312-020-1997-1
  10. Riphagen S, Gomez X, Gonzalez-Martinez C, et al. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet 2020;395(10237):1607–1608. DOI: 10.1016/S0140-6736(20)31094-1
  11. Shobhavat L, Solomon R, Rao S, et al. Multisystem inflammatory syndrome in children: clinical features and management—intensive care experience from a pediatric public hospital in Western India. Indian J Crit Care Med 2020;24(11):1089–1094. DOI: 10.5005/jp-journals-10071-23658
  12. Dhanalakshmi K, Venkataraman A, Balasubramanian S, et al. Epidemiological and clinical profile of pediatric inflammatory multisystem syndrome—temporally associated with SARS-CoV-2(PIMS-TS) in Indian children. Indian Pediatr 2020;57(11):1010–1014. DOI: 10.1007/s13312-020-2025-1
  13. Sugunan S, Bindusha S, Geetha S, et al. Clinical profile and short-term outcome of children with SARS-CoV-2 related multisystem inflammatory syndrome (MIS-C) treated with pulse methylprednisolone. Indian Pediatr 2021;58(8):718–722. DOI: 10.1007/s13312-021-2277-4
  14. Ahmed M, Advani S, Moreira A, et al. Multisystem inflammatory syndrome in children: a systematic review. EClinicalMedicine 2020;26:100527. DOI:
  15. Matsubara D, Kauffman HL, Wang Y, et al. Echocardiographic findings in pediatric multisystem inflammatory syndrome associated with COVID-19 in the United States. J Am Coll Cardiol 2020;76(17):1947–1961. DOI: 10.1016/j.jacc.2020.08.056
  16. Gregoriano C, Heilmann E, Molitor A, et al. Role of procalcitonin use in the management of sepsis. J Thorac Dis 2020;12(Suppl 1):S5–S15. DOI: 10.21037/jtd.2019.11.63
  17. Bay M, Kirk V, Parner J, et al. NT-proBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function. Heart 2003;89(2):150–154. DOI: 10.1136/heart.89.2.150
  18. Masutani S, Saiki H, Kurishima C, et al. Heart failure with preserved ejection fraction in children–hormonal imbalance between aldosterone and brain natriuretic peptide. Circ J 2013;77(9): 2375–2382. DOI: 10.1253/circj.cj-12-1271
  19. Blondiaux E, Parisot P, Redheuil A, et al. Cardiac MRI of children with Multisystem Inflammatory Syndrome (MIS-C) associated with COVID-19: case series. Radiology 2020;297(3):E283–E288. DOI: 10.1148/radiol.2020202288
  20. McArdle AJ, Vito O, Patel H, et al. Treatment of multisystem inflammatory syndrome in children. N Engl J Med 2021;385(1):11–22. DOI: 10.1056/NEJMoa2102968
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.